IFN-γ at the Site of Infection Determines Rate of Clearance of Infection in Cryptococcal Meningitis
- 1 February 2005
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 174 (3), 1746-1750
- https://doi.org/10.4049/jimmunol.174.3.1746
Abstract
In animal models, immunity to cryptococcal infection, as in many chronic fungal and bacterial infections, is associated with a granulomatous inflammatory response, intact cell-mediated immunity, and a Th1 pattern of cytokine release. To examine the correlates of human immunity to cryptococcal infection in vivo, we analyzed immune parameters at the site of infection over time and assessed the rate of clearance of infection by serial quantitative cerebrospinal fluid (CSF) fungal cultures in 62 patients in a trial of antifungal therapy for HIV-associated cryptococcal meningitis. CSF IL-6, IFN-γ, TNF-α, and IL-8 were significantly higher in survivors compared with nonsurvivors. There were negative correlations between log TNF-α, IFN-γ, and IL-6 levels and baseline cryptococcal CFU. Log IFN-γ, G-CSF, TNF-α, and IL-6 were correlated positively with the rate of fall in log CFU/ml CSF/day. In a linear regression model including antifungal treatment group, baseline CFU, and these cytokines, only treatment group and log IFN-γ remained independently associated with rate of clearance of infection. The results provide direct in vivo evidence for the importance of quantitative differences in IFN-γ secretion in human immune control of granulomatous infections, and increase the rationale for adjunctive IFN-γ in the treatment of refractory HIV-associated cryptococcosis.Keywords
This publication has 27 references indexed in Scilit:
- Recombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal MeningitisThe Journal of Infectious Diseases, 2004
- Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trialThe Lancet, 2004
- Morbidity and Mortality in South African Gold Miners: Impact of Untreated Disease Due to Human Immunodeficiency VirusClinical Infectious Diseases, 2002
- Clinical Presentation and Risk Behaviors of Patients with Acquired Immunodeficiency Syndrome in Thailand, 1994-1998: Regional Variation and Temporal TrendsClinical Infectious Diseases, 2001
- 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trialThe Lancet, 2000
- Cryptococcosis in AIDSPostgraduate Medical Journal, 2000
- Early Mycological Treatment Failure in AIDS‐Associated Cryptococcal MeningitisClinical Infectious Diseases, 1999
- Cryptococcus neoformansPublished by American Society for Microbiology ,1998
- Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in UgandaInternational Journal of Epidemiology, 1998
- Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1997